Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. - Wikidata - wikimedia - TriplyDB

Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.

Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.

http://www.wikidata.org/entity/Q37450606

about

How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.Magnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlations MRI in breast cancer therapy monitoring Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.Correlation between Blood Flow Signal of Color Flow Imaging and Nottingham Prognostic Index in Patients with Breast Carcinoma.Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis Early prediction of response to neoadjuvant chemotherapy for locally advanced breast cancer using MRI Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.Changes of T2 Relaxation Time From Neoadjuvant Chemotherapy in Breast Cancer Lesions.Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.

P2860

Q26798419-660BA1FB-9AE1-49E4-8982-DADC042D9B57 Q27024544-F0B9DB99-5654-4E7D-87ED-7B08FE03D196 Q30651989-D476D892-3A68-436F-9C6E-4A979FE11561 Q33933029-B7553BE7-3CD9-42AE-A929-A7235A958BAF Q33938324-708C45DB-8E78-4D31-9C93-DB234D7A286A Q34074868-5F38D49A-81BE-4A75-89F4-6D9FA14A467A Q34940150-B3B4D350-51A3-4EBA-831C-A30080132FBF Q35560975-6611E8EE-4F3A-4A74-8BE6-C02612A4C672 Q35928203-2AA6D26E-742D-4DF9-AB66-30A6D047B941 Q36036146-AB557492-1FD4-4B45-A03A-84E869CF13A7 Q36118278-AA13EB8A-F0C7-45CE-8AFF-FA100E9250A3 Q36797054-874C8828-4C32-4498-AB18-CA4F569F904E Q37180350-40083896-8B13-422C-B257-C48200DB5662 Q37410448-E10CA7D9-86AC-44BC-8E8A-72E537FEA623 Q37734922-40BD51CB-A3B9-4865-A323-E10B59E8457E Q44491240-9868C551-AE79-40B8-A135-DC2804E0CDB9 Q53080309-B542B1DC-05EF-4BEC-A62D-7DAD4275977C Q54446011-B811C146-D440-4B6B-AF5B-87C9232F861D

P2860

Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.

http://www.wikidata.org/entity/Q37450606

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Residual breast cancer diagnos ...... with and without bevacizumab.

@en

Residual breast cancer diagnos ...... with and without bevacizumab.

@nl

type

label

Residual breast cancer diagnos ...... with and without bevacizumab.

@en

Residual breast cancer diagnos ...... with and without bevacizumab.

@nl

prefLabel

Residual breast cancer diagnos ...... with and without bevacizumab.

@en

Residual breast cancer diagnos ...... with and without bevacizumab.

@nl

P1433

Q37450606-5CB0F3E0-B345-44AB-9EA5-A0FF752C559F

P1476

Q37450606-161A9FBD-92F2-45B2-96E8-73A970E897DD

P2093

Q37450606-11A813CE-8ABF-44B0-910A-0EF11625D69E

Q37450606-1DCDBFF5-0BA3-48A9-A2E5-3923B3E3023E

Q37450606-2E4F7AAA-D2D9-49B1-9B1C-13812DDEC6FC

Q37450606-36D837F2-D8C4-486E-85D3-0D554C777BFB

Q37450606-4E93CD56-F5D1-476E-9FC9-2131C98D4464

Q37450606-7160C800-8AF7-4189-92A2-FDFF80B9B81D

Q37450606-C34F9F32-3A43-4C4B-8020-531C8140DAB3

Q37450606-CA54DBB8-9F4A-4DEF-8EB9-A1AF86AB6AFB

Q37450606-F0AC6E02-84B9-4EC5-919E-D733AC67F36D

P2860

Q37450606-035A7105-D9B1-4F9C-9459-812FE70E0BA3

Q37450606-155113E2-2D59-4BB3-BDAD-8E78E3BFDD56

Q37450606-1BA928EB-BCF2-44AB-A6D6-421A1CB3FFAC

Q37450606-1BBA1515-EEFF-43BA-B4EB-A5A6C8FA019F

Q37450606-22606EE1-AE5E-4E72-BFD2-294B3B0A46E0

Q37450606-22EA7136-AD0D-4631-8BD1-5880D17CAC70

Q37450606-2704B9EA-1072-405B-A240-6EF35D411458

Q37450606-2FD2D2FD-148E-4569-BA7F-4DEC2FB1CAB3

Q37450606-340C26BA-193E-4AC0-8568-B952B220D442

Q37450606-35E59A37-294C-4D0E-9EAD-EAE141686C90

P2888

Q37450606-3C5B706D-E105-41D4-B58F-2CEB222AC006

P304

Q37450606-49AE8B0A-5605-4FE4-9122-A911C47E5FC1

P31

Q37450606-ACB1E113-62A3-44AA-B121-107C868AD6DA

P356

Q37450606-9C66425A-41E4-4926-ACFC-1D4A85D58E40

P433

Q37450606-CBCFAEC6-BB62-41A2-82F7-C817783BFD87

P478

Q37450606-4C0F77A9-B2F3-4A22-AEE7-47DF92174E3F

P577

Q37450606-500A5487-462B-447A-94BD-AFC8E1800EFC

P5875

Q37450606-FC63D1A7-A475-4E56-82E1-8AB5BB5344D5

P6179

Q37450606-32EC789E-51C5-4F29-9E36-516EC57F0E46

P698

Q37450606-9E293B85-80DB-43DD-87AD-5DE835FDDDE7

P921

Q37450606-8D76A07E-4B61-4CEC-BFC5-AADAD0ADE28E

Q37450606-C2ED4540-60FF-4EBB-8CD7-A5A44B3A55CA

P932

Q37450606-91D183A9-4E3A-4AD0-925B-42E31533A25B

P356

S10434-009-0441-5

P1433

Annals of Surgical Oncology

P1476

Residual breast cancer diagnos ...... with and without bevacizumab.

@en

P2093

Hon J Yu

http://www.w3.org/2001/XMLSchema#string

Jeon-Hor Chen

http://www.w3.org/2001/XMLSchema#string

Ke Nie

http://www.w3.org/2001/XMLSchema#string

Min-Ying Su

http://www.w3.org/2001/XMLSchema#string

Orhan Nalcioglu

http://www.w3.org/2001/XMLSchema#string

Philip M Carpenter

http://www.w3.org/2001/XMLSchema#string

Rita S Mehta

http://www.w3.org/2001/XMLSchema#string

Shadfar Bahri

http://www.w3.org/2001/XMLSchema#string

Soon-Young Kwon

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

What is the evidence that tumors are angiogenesis dependent?

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

P2888

s10434-009-0441-5

P304

1619-1628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-009-0441-5

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24245931

http://www.w3.org/2001/XMLSchema#string

P6179

1036272912

http://www.w3.org/2001/XMLSchema#string

P698

19333654

http://www.w3.org/2001/XMLSchema#string

P921

P932

2786305

http://www.w3.org/2001/XMLSchema#string